Meta AnalysisID 2744
组胺H3受体拮抗剂控制抗精神病药相关体重增加的疗效和安全性：系统评价和Meta分析
CRD42020150055
To examine whether histamine H3 antagonists is effective in controlling antipsychotic-related weight gain.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2744
- Evidence Id
- 11302
- Core Evidence Id
- 11302
- Source Meta Analysis Id
- 2694
- Herb2 Meta Analysis Id
- HBMA002694
- Crd Id
- CRD42020150055
- Title
- The efficacy and safety of histamine H3 antagonists in controlling antipsychotic-related weight gain: a systematic review and meta-analysis
- Review Question
- To examine whether histamine H3 antagonists is effective in controlling antipsychotic-related weight gain.
- Study Type Included
- Randomized, placebo-controlled trials of histamine H3 antagonists lasting ≥6 months in patients with schizophrenia or schizoaffective disorders, and who are not suffering from any severe organic diseases, such as myocardial infarction or liver cirrhosis.
- Condition Being Studied
- Over the last two decades antipsychotics are increasingly prescribed to children and adolescents in many countries. In particular, there has been a widespread use of second generation antipsychotic (SGA) treatment in children and adolescents with diagnosis of several psychiatric disorders. Among children and adolescents, weight gain or increase of body mass index (BMI) emerge as one of the most relevant side effects of SGA, with an ensuing risk of type II diabetes, cardiovascular morbidity and metabolic syndrome. The prevalence of overweight among hospitalised children and adolescents with exposure to SGAs is triple that of national norms in the United States. An excessive BMI among children and adolescents with psychiatric disorders may have other deleterious effects such as stigmatisation and further social withdrawal.
- Participant
- Exclusion: patients with schizophrenia or schizoaffective disorders treated with antipsychotic drugs. Exclusion: patients with severe organic diseases.
- Animal
- Human Disease Modelled
- Intervention
- Histamine H3 antagonists
- Comparator Control
- Placebo
- Main Outcome
- Body Mass Index (BMI) Measures of effect Body Mass Index (BMI) is a person’s weight in kilograms divided by the square of height in meters.
- Outcome Measure
- Additional Outcome
- Random or fasting levels of glucose, blood lipid levels, improvement in psychotic symptoms (endpoint scores or changes in scores on the SANS and SAPA) and incidence of individual adverse events. Measures of effect Endpoint scores or changes in scores will be assessed.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Antipsychotic Agents; Histamine H3 Antagonists; Humans; Weight Gain
- Contact
- Jianzhao Zhang [email protected]
- Organisational Affiliation
- Nanchang University http://www.ncu.edu.cn/
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-09-12
- Registration Date
- 2020-07-22
- Anticipated Start Date
- 2019-09-13
- Anticipated Completion Date
- 2020-01-31
- Title Cn
- 组胺H3受体拮抗剂控制抗精神病药相关体重增加的疗效和安全性：系统评价和Meta分析
- Title En
- The efficacy and safety of histamine H3 antagonists in controlling antipsychotic-related weight gain: a systematic review and meta-analysis
- Bilingual Status
- complete